Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ADR Biomedical Holdings's revenue for the
three
months ended in Mar. 2026 was 円17.29 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was 円50.99 Mil.
ADR Biomedical Holdings's Revenue per Share for the
three
months ended in Mar. 2026 was 円1.94.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円5.71.
Warning Sign:
ADR Biomedical Holdings Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of ADR Biomedical Holdings was -58.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -71.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -50.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -25.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, ADR Biomedical Holdings's highest 3-Year average Revenue per Share Growth Rate was 30.20% per year. The lowest was -71.20% per year. And the median was -20.75% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ADR Biomedical Holdings's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADR Biomedical Holdings Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADR Biomedical Holdings's Revenue distribution charts can be found below:
* The bar in red indicates where ADR Biomedical Holdings's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円50.99 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADR Biomedical Holdings (TSE:3750) has a Revenue of 円50.99 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on ADR Biomedical Holdings and its competitors.
Is ADR Biomedical Holdings' Revenue too high?
ADR Biomedical Holdings' current Revenue is 円50.99 Mil. Overall, ADR Biomedical Holdings has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ADR Biomedical Holdings' Revenue compare to VRTX and REGN?
ADR Biomedical Holdings' Revenue of 円50.99 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on ADR Biomedical Holdings and its competitors. ADR Biomedical Holdings's current Revenue is 円50.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADR Biomedical Holdings stock overvalued right now?
Based on GuruFocus' analysis, ADR Biomedical Holdings (TSE:3750) is currently considered Significantly Overvalued. The stock's GF Value™ is 円39.51, compared to a current price of 円792.00 — trading 1904.6% above its estimated fair value. The current Revenue is 円50.99 Mil. ADR Biomedical Holdings' overall GF Score™ is 28/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For ADR Biomedical Holdings (TSE:3750), the current Revenue is 円50.99 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADR Biomedical Holdings (TSE:3750) Overvalued in 2026?
Based on GuruFocus' analysis, ADR Biomedical Holdings stock appears to be overvalued.
The current stock price of 円792.00 is trading 1904.6% above its estimated GF Value™ of 円39.51.
GuruFocus considers ADR Biomedical Holdings to be Significantly Overvalued.
Key valuation signals for TSE:3750:
Revenue: 円50.99 Mil
GF Value™: 円39.51 vs. price of 円792.00 (1904.6% above fair value)
No single metric tells the full story. See the TSE:3750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADR120S Inc developing a new clinical approach to cell therapy to provide medical care to patients by providing medical care that responds to unmet medical needs based on its regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.
28GF Score
Get the complete analysis for TSE:3750
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3750 has been successfully added to your 
